Hengrui Pharma(SH:600276) Cai Jing Wang·2025-12-29 03:08Core Viewpoint - Recently, Heng Rui Medicine (600276) signed an exclusive licensing agreement with Hansoh Pharmaceutical Group Co., Ltd. to license its SHR6508 project, which is currently in Phase III clinical trials for treating secondary hyperparathyroidism in chronic kidney disease patients undergoing dialysis [1] Group 1: Licensing Agreement - The licensing agreement involves a payment of RMB 30 million as an upfront fee from Hansoh Pharmaceutical to Heng Rui Medicine [1] - Heng Rui Medicine is eligible to receive regulatory milestone payments and commercial milestone payments related to the inclusion of the licensed product in the national medical insurance directory, which can total up to RMB 190 million [1] - The company is entitled to a tiered sales commission based on quarterly net sales, with a maximum rate of 9% [1] Group 2: Product Details - SHR6508 is a novel calcium-sensing receptor allosteric modulator intended for the treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease requiring dialysis [1] - The mechanism of SHR6508 involves enhancing sensitivity to calcium ions, which reduces the secretion of parathyroid hormone (PTH) in patients with secondary hyperparathyroidism [1] Group 3: Related Parties - Hansoh Pharmaceutical and its subsidiary, Jiangsu Hengrui Pharmaceutical Group Co., Ltd., are considered related parties due to the control of the company's actual controller and chairman, Sun Piaoyang, by his spouse [1] - This transaction constitutes a related party transaction as per the listing rules [1]